SK Pharmteco

What SK Pharmteco does

SK Pharmteco is a global contract development and manufacturing organization (CDMO) and wholly-owned subsidiary of South Korea's SK Inc., formed in December 2024 through the consolidation and rebrand of SK Biotek, YposKesi, and Center for Breakthrough Medicines. The company operates three business units—small molecules, peptides, and viral vectors—serving pharmaceutical and biotechnology developers from early clinical development through commercial scale. Headquartered in Rancho Cordova, California, SK Pharmteco employs more than 10,000 people across CGMP manufacturing facilities in the United States (California, Texas, Pennsylvania), Europe (Ireland, France), and South Korea, with over 1,000 m³ of small molecule capacity and 5,000+ liters of viral vector bioreactor capacity.

The company's technology platform centers on the proprietary SKyvec™ multimodal viral vector system (AAV, lentiviral, adenoviral), a Universal CGMP HEK293 cell line (Clone 4G9), the Analytical Accelerator™ testing platform that reduces batch release time more than three-fold, seven Simulated Moving Bed chromatography units (including the largest in North America), continuous flow processing under extreme conditions (up to 300 bar, 600°C), HPAPI containment to 10 ng/m³ OEL, and a 6,000+ enzyme biocatalyst library accessed through the Prozomix partnership. The company is pursuing SBTi-validated net-zero emissions by 2040 and holds multiple My Green Lab certifications. Revenue is generated primarily through fee-for-service CDMO contracts, project-based and scale-dependent, spanning clinical trial materials through commercial API and viral vector production, with multi-year commercial manufacturing relationships providing recurring revenue visibility—a $1.4 billion GLP-1 manufacturing deal secured in December 2024 is the largest disclosed commercial anchor.

Name

SK Pharmteco

Legal name

SK pharmteco Inc.

Website

https://skpharmteco.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

SK Pharmteco is a global CDMO and subsidiary of SK Inc., offering integrated small molecule, peptide, and viral vector manufacturing services to pharmaceutical and biotechnology companies across the U.S., Europe, and South Korea.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Contract pharmaceutical manufacturing
• Viral vector CDMO services
• Small molecule API manufacturing
• Peptide synthesis manufacturing
• Gene therapy manufacturing

Headquarters

HQ city

Rancho Cordova

HQ country

United States

HQ region

North America

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. CDMO Manufacturing Services (Small Molecules, Peptides, Viral Vectors): SK pharmteco generates revenue primarily through fee-for-service CDMO contracts covering process development, analytical development, CGMP manufacturing, and quality control services. Revenue is project-based and scale-dependent, spanning clinical trial materials manufacturing through commercial-scale API and viral vector production. The company operates across three business units (small molecules, peptides, viral vectors) and serves pharmaceutical and biotech clients globally, with multi-year commercial manufacturing relationships providing recurring revenue visibility.
2. Viral Vector Manufacturing: Viral vector CDMO services including AAV, lentiviral, and adenoviral vector manufacturing from early development through commercial supply. The company has invested $100 million to expand viral vector capabilities in Pennsylvania and France, positioning for growth in the high-value gene therapy CDMO market. Manufacturing scales up to 1,000 liters (U.S.) and 2,000 liters (France) under GMP conditions.
3. SKyvec™ Platform Licensing/Access: Access to proprietary multimodal viral vector platforms (AAV, Lentiviral, Adenoviral) combined with manufacturing services, with process enhancements delivering 5x–6x productivity gains. Platform is positioned as a differentiated offering that addresses industry scalability and cost challenges in gene therapy manufacturing.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

SK Pharmteco is a global contract development and manufacturing organization (CDMO) providing pharmaceutical manufacturing services across three business units: small molecules (APIs, intermediates, HPAPIs, ADC payloads), peptides (synthesis and purification), and viral vectors (AAV, lentiviral, adenoviral). The company operates CGMP facilities across the U.S., Europe, and South Korea, delivering end-to-end services from process development and analytical testing through clinical and commercial-scale manufacturing for pharmaceutical and biotechnology clients.

Product overview

SK pharmteco is a global contract development and manufacturing organization (CDMO) organized around three core business units: Small Molecules, Peptides, and Viral Vectors. The company operates as a unified platform providing end-to-end pharmaceutical manufacturing services from early development through commercial scale. The Small Molecules unit encompasses API drug development, custom manufacturing, and specialty capabilities including chromatography, energetic chemistry, HPAPIs, continuous flow processing, particle engineering, catalyst design, and biocatalysis. The Peptides unit provides integrated peptide synthesis and purification services. The Viral Vectors unit is anchored by the proprietary SKyvec™ multimodal platform supporting AAV, lentiviral, and adenoviral vector manufacturing, complemented by the AAVelocity platform. Supporting services include analytical testing, regulatory support, cell and viral banking, fill-finish operations, and rare disease program support. The company operates CGMP facilities across the U.S. (California, Texas, Pennsylvania), Europe (Ireland, France), and South Korea.

Differentiator

Problem solved

Functional benefit

Products and services

• Small Molecule CDMO Services Scalable small molecule development and manufacturing of active pharmaceutical ingredients (APIs), regulatory starting materials, advanced intermediates, and high-potency APIs spanning from grams to multi-tons under CGMP compliance, including specialty capabilities such as chromatography, energetic chemistry, continuous flow processing, particle engineering, catalyst design, and biocatalysis.
• Peptide CDMO Services Integrated peptide development and manufacturing combining advanced synthesis (SPPS, LPPS, hybrid approaches), chromatographic purification, and in-house analytics for clinical to commercial scale peptide APIs, supporting peptide therapeutics including GLP-1 receptor agonists for metabolic disease applications.
• Viral Vector CDMO Services Viral vector manufacturing platforms and customized solutions for AAV, lentiviral, and adenoviral vectors supporting programs from early development through clinical and commercial manufacturing, including process development, CGMP drug substance manufacturing, aseptic fill-finish, cell and viral banking, and analytical services.
• SKyvec™ Viral Vector Platform Harmonized multimodal viral vector platform integrating AAV, lentiviral, and adenoviral vector process development, manufacturing, and scale-up. Combines the Universal CGMP HEK293 cell line (clone 4G9), off-the-shelf plasmid technologies, and proprietary processing enhancements to support gene therapy programs from early research through commercial manufacturing across North America and Europe.
• Analytical Services End-to-end analytical services including method development and validation, raw material testing, characterization, release testing, and stability studies for small molecule APIs, peptides, and viral vectors. Includes the proprietary Analytical Accelerator™ Testing Platform that speeds CGMP batch release more than three-fold and conserves sample volumes by up to 50 percent.
• Regulatory Support Services

Quantifiable outcome

• 5x to 6x productivity gains in viral vector manufacturing through SKyvec™ platform
• +9 more outcomes

Named customers11 records

Segments6 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Nine partnerships are on record, tiered strategic and core.

• Orphan ClinDevNet (Orphan Therapeutics Accelerator Network)strategicStrategic or Co-development Partner · 23 June 2026SK pharmteco joined Orphan Therapeutics Accelerator's expanded development network, Orphan ClinDevNet, alongside OPIS, Uniphar, and TMC Pharma. The network provides a decentralized, outsourced infrastructure for development and commercialization of ultra-rare disease therapies. SK pharmteco contributes U.S.-based viral vector manufacturing capabilities to the network.
• Orphan Therapeutics Accelerator (OTXL)coreStrategic or Co-development Partner · 18 June 2026Strategic collaboration making SK pharmteco OTXL's preferred technical partner for manufacturing services for rare disease therapies. SK pharmteco provides priority access and preferential rates for up to two therapeutic programs per year, encompassing process development, analytical development, and GMP manufacturing. The partnership aligns with SK pharmteco's Rare Disease Advancement Initiative and aims to address common manufacturing challenges preventing rare disease programs from progressing to clinical and commercial stages. OTXL is a non-profit biotech focused on advancing stalled rare disease treatments.
• National Institutes of Health (NIH)coreStrategic or Co-development Partner · 7 May 2026SK pharmteco serves as subcontractor to NIH (with Axle Informatics as prime contractor) for gene therapy programs for rare diseases, focusing on viral vector programs including lentiviral vectors for treating rare hereditary blood and metabolic disorders. SK pharmteco manufactured drug substance and conducted batch release testing for ex vivo transduction of patients' CD34+ hematopoietic stem cells. The collaboration combines SK pharmteco's advanced manufacturing capabilities with NIH principal investigators to accelerate academic research into clinical practice.
• Axle InformaticscoreStrategic or Co-development Partner · 7 May 2026Axle Informatics serves as the primary contractor to NIH for gene therapy programs, with SK pharmteco as subcontractor providing viral vector manufacturing and analytical support. The collaboration leverages Axle's bioinformatics and program coordination expertise with SK pharmteco's manufacturing capabilities for rare disease gene therapy development.
• ProzomixcoreTechnology or Integration · 24 March 2026Strategic partnership integrating Prozomix's biocatalyst libraries (over 6,000 diverse native biocatalysts) into SK pharmteco's small-molecule development and manufacturing services across R&D centers in the U.S., Europe, and Asia. The collaboration enables rapid identification of high-performing enzymes for complex Active Pharmaceutical Ingredient synthesis, accelerating adoption of sustainable, enzyme-based manufacturing processes. The deal expands SK pharmteco's technology offerings while providing Prozomix access to a broader spectrum of high-value pharmaceutical projects through SK pharmteco's worldwide manufacturing network.
• Lotte BiologicsstrategicStrategic or Co-development Partner · 29 October 2025Strategic partnership between SK pharmteco and Lotte Biologics to strengthen global ADC CDMO capabilities. The collaboration aims to enhance both companies' positions in the antibody-drug conjugate contract development and manufacturing organization market, strengthening their global presence in this biotech sector through complementary capabilities.
• AaviGenstrategicStrategic or Co-development Partner · 1 October 2024Strategic partnership to manufacture AaviGen's lead gene therapy product for heart failure. SK pharmteco provides viral vector manufacturing and development services for AaviGen's cardiac gene therapy program, supporting the company's advancement toward clinical stages.
• CryoportstrategicTechnology or Integration · 25 September 2024Partnership for cell and gene therapy logistics and BioServices. Cryoport provides specialized logistics solutions for temperature-sensitive biological materials, complementing SK pharmteco's manufacturing capabilities for cell and gene therapy products requiring reliable cold-chain distribution.
• RznomicsstrategicStrategic or Co-development Partner · 6 August 2024SK pharmteco and Rznomics signed a Memorandum of Understanding (MoU) to explore collaboration for RNA-based gene therapy development and manufacturing. The partnership aims to combine SK pharmteco's CDMO capabilities with Rznomics' RNA-based gene therapy platform to support development and manufacturing of innovative RNA-based therapeutics.

Scale indicators22 records

Recent moves9 records

Expansion highlights8 records

Direct peers

• Lonza Group: World's largest CDMO offering integrated small molecule, biologics, and cell & gene therapy manufacturing services globally. Directly comparable as a multi-modality CDMO serving pharma and biotech with similar end-to-end capabilities.
• AGC Biologics: Global CDMO specializing in biologics and viral vector/ cell and gene therapy manufacturing. Closely comparable as a viral vector CDMO with similar gene therapy customer base and manufacturing capabilities.
• Lotte Biologics: Korean CDMO with biologics manufacturing and growing ADC capabilities. Comparable as a Korean-headquartered CDMO peer and strategic ADC partnership partner to SK pharmteco.
• Catalent: Major global CDMO (now owned by Novo Holdings) providing small molecule and biologic drug substance and drug product services. Closely comparable in CDMO scope across modalities and customer base.
• WuXi AppTec / WuXi Biologics: Global CDMO offering small molecule API manufacturing, biologics, viral vectors, and integrated CMC services. Direct peer across multiple CDMO modalities including viral vector manufacturing.
• Recipharm: European CDMO providing small molecule API and finished dosage form manufacturing. Comparable as a multi-site small molecule CDMO serving similar pharmaceutical customers globally.
• Samsung Biologics: Korean biologics CDMO and direct domestic peer within SK pharmteco's Korean ecosystem. Comparable as a large-scale contract manufacturer with biologics and increasingly small molecule capabilities for global pharma.
• Boehringer Ingelheim BioXcellence: Biopharmaceutical contract manufacturing arm of Boehringer Ingelheim offering biologics and viral vector CDMO services. Comparable as a multi-modality CDMO serving similar pharma/biotech customers.

Broad incumbents

• Thermo Fisher Scientific (Patheon): Operates a major CDMO segment (Patheon) plus broader life sciences tools and services. Comparable in small molecule and biologic CDMO services as part of a much larger diversified life sciences platform.

Others

• Center for Breakthrough Medicines (now part of SK pharmteco): Acquired by SK pharmteco in 2023, expanding multi-modality and radiopharmaceutical capabilities. Referenced as a historical peer now integrated into the subject company for cell and gene therapy CDMO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@SK_pharmteco
• LinkedInlinkedin.com/company/skpharmteco
• Xx.com/skpharmteco
• Facebookfacebook.com/profile.php

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SK Pharmteco